<DOC>
	<DOCNO>NCT00436657</DOCNO>
	<brief_summary>There successful treatment diffuse peritoneal metastasis carcinomatosis , childhood tumor . Once advanced stage disease evident , survival measure week . The selective lethal effect supranormal temperature neoplastic cell additive synergistic effect combine chemotherapy well establish adult clinical trial use continuous hyperthermic peritoneal perfusion ( CHPP ) advance peritoneal adenocarcinoma gastrointestinal origin , ovarian carcinoma mesothelioma . This phase I study evaluate safety continuous hyperthermic peritoneal perfusion escalate dos intraperitoneal cisplatin treatment child refractory tumor limit abdominal cavity . If tumor outside abdominal cavity , tumor must able control . Since CHPP potential improve outcome child peritoneal retroperitoneal metastasis , study evaluate safety elevate temperature ( 40oC ) intraperitoneal cisplatin chemotherapy . Primary Objectives : 1 . To determine MTD dose-limiting toxicity intraperitoneal cisplatin give combination CHPP 90 minute perfusion child advance peritoneal retroperitoneal solid tumor 2 . To determine safe tolerable dose CHPP cisplatin use Phase II trial 3 . To determine pharmacokinetics intraperitoneal cisplatin platinum give CHPP 90 minute abdominal perfusion ( Optional )</brief_summary>
	<brief_title>Continuous Hyperthermic Peritoneal Perfusion ( CHPP ) With Cisplatin Children With Peritoneal Cancer</brief_title>
	<detailed_description>Cisplatin atom center contain platinum . The platinum suppose poison cancer cell , cause eventually die . Sodium thiosulfate design bind-up Cisplatin escape abdomen blood stream . This investigational treatment perform two child compassionate use basis North America . Both surgery perform M.D . Anderson Study Chairman . Before start receiving study drug , `` screening test . '' These test help doctor decide eligible take part study . A physical exam perform , compute tomography ( CT ) scan , magnetic resonance imaging ( MRI ) scan make sure disease abdomen ( stomach area ) . Blood ( 1 teaspoon ) drawn routine test . You may echocardiogram ( ECHO -- test check heart function ) , electrocardiogram ( ECG -- test measure electrical activity heart ) ever take anthracycline drug . An echocardiogram us sound wave make picture heart , help show well heart pump blood . You ask lie left side technician place probe gel chest create image heart determine function size . Women able child must negative urine pregnancy test . If find eligible , hear test surgery one-month evaluation . If find eligible , abdominal surgery perform try remove many tumor possible . The surgeon may decide surgery abdominal wash perform , example disease spread attach certain organ . If occurs , doctor discus treatment option . If doctor decides eligible receive abdominal wash , drug call sodium thiosulfate give needle vein . The abdomen temporarily close . Then abdominal wash begin . This do room anesthesia . During `` abdominal wash , '' heat cisplatin give abdomen `` wash '' area surgical procedure . There pump attach plastic tube pump drug abdomen 90 minute period surgeon gently compress abdominal wall drug reach area abdomen equally . After 90 minute drug remove abdomen 'washed ' saline . Then fluid remove surgeon permanently close abdomen 3 layer stitch . The actual dose level cisplatin receive decide enter study . Participants study enrol group 3 , group give specific dose level cisplatin . The first group receive low dose cisplatin . If severe life-threatening side effect first group patient , next group receive high dose cisplatin . This process increase dose level new group participant continue patient severe life-threatening side effect . At point , dose level cisplatin lower tested participant . Blood ( 1 teaspoon ) drawn routine test . This test take place operation every day leave hospital . After leave hospital , study visit 1 month later , every 3 month 6 month . At visit , CT scan MRI scan physical exam check status disease . You take study disease get bad disease free 6 month follow-up . This investigational study . Cisplatin FDA-approved commercially available . Up 18 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
	<mesh_term>Retroperitoneal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Age great equal 3 less equal 18 year 2 . Histologically proven diffuse peritoneal retroperitoneal tumor follow histology : adenocarcinoma gastrointestinal tract , desmoplastic round cell tumor , late stage neuroblastoma , ovarian germ cell , sarcoma , adrenocorticocarcinoma , Wilms ' , rhabdomyosarcoma . ( target group : desmoplastic small round cell tumor ( DSRCT ) , neuroblastoma , recurrent tumor ) . If tumor outside abdominal cavity , tumor must controllable . 3 . All patient must refractory recurrent tumor know curative treatment option . 4 . Radiologic workup must demonstrate disease confine abdominal cavity . If tumor outside abdominal cavity , tumor must able control . 5 . Radiologic workup prior abdominal exploration must consistent disease debulked residual size less equal 1 mm thickness per tumor deposit 6 . Patients must minimum expected duration survival great 6 week 7 . Patients must systemic illness precludes operative candidate . This include limited sepsis , liver failure , pregnancy , lactate female . 8 . Patients must fully intact mental status normal neurologic ability . 9 . Patients must adequate renal function ( serum creatinine &lt; /= 1.5 without history dialysis renal failure ) 10 . Patients eligible white blood count ( WBC ) &gt; =2,000/ul Absolute neutrophil count ( ANC ) &gt; =1,500 , platelets &gt; = 100,000/mm^3 11 . Patients eligible serum total bilirubin liver enzyme ( aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ) &lt; /= 2 time upper limit normal 12 . Patients must recover toxicity prior chemotherapy , immunotherapy , radiotherapy least 14 day past date last treatment 13 . If tumor outside abdominal cavity , tumor must controllable . 1 . Patients fail previous continuous hyperthermic intraperitoneal perfusion platinum therapy ineligible 2 . Patients tumor unable control outside abdominal cavity ineligible 3 . Patients ineligible concomitant cardiopulmonary disease would place unacceptable risk major surgical procedure 4 . Patients ineligible baseline neurologic toxicity Grade 3 great ( potential neurotoxicity associate platinum )</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Children</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Peritoneal Tumor</keyword>
	<keyword>Retroperitoneal Tumor</keyword>
	<keyword>Gastrointestinal Adenocarcinoma</keyword>
	<keyword>Desmoplastic Round Cell Tumor</keyword>
	<keyword>Neuroblastoma</keyword>
	<keyword>Ovarian Germ Cell</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Adrenocorticocarcinoma</keyword>
	<keyword>Wilms ' Tumor</keyword>
	<keyword>Rhabdomyosarcoma</keyword>
	<keyword>Desmoplastic Small Round Cell Tumor</keyword>
	<keyword>Recurrent Tumors</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Platinol®-AQ</keyword>
	<keyword>Platinol®</keyword>
	<keyword>CDDP</keyword>
	<keyword>Abdominal Wash</keyword>
	<keyword>Hyperthermic Perfusion</keyword>
	<keyword>Continuous Hyperthermic Peritoneal Perfusion</keyword>
	<keyword>CHPP</keyword>
</DOC>